Ruth Ann Vleugels, MD
Dermatology · Boston, MANPI 1124154554
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $257,278 of the $368,259 with a category attached, or 69.9%. It is spread thinly across 20 manufacturers, the largest accounting for just 20.7%. 2025 is the largest year on record at $192,879, more than ten times the $2,434 reported in 2019. Among dermatology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 218 payments — averaging $1689.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$76K
- Astrazeneca UK Limited$73K
- Lilly USA, LLC$70K
- E.r. Squibb & Sons, L.L.C.$30K
- AbbVie$28K
- Pfizer$25K
- plus $66K from 14 others
Across 67 payments — averaging $6342.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$269K
- Astrazeneca UK Limited$101K
- AstraZeneca$30K
- Janssen Research & Development, LLC$22K
- EMD Serono, Inc.$2K
- AbbVie$665
What the payments were for
- Consulting fees$257,27870%
- Speaking & faculty fees$61,77517%
- Travel & lodging$43,93512%
- Food & beverage$5,2701%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 47 | $76,109 |
| Astrazeneca UK Limited | 37 | $72,916 |
| Lilly USA, LLC | 31 | $70,190 |
| E.r. Squibb & Sons, L.L.C. | 22 | $29,977 |
| AbbVie | 33 | $27,905 |
| Pfizer | 6 | $25,222 |
| Johnson & Johnson | 18 | $16,573 |
| Boehringer Ingelheim International GmbH | 3 | $16,357 |
| AstraZeneca | 3 | $8,888 |
| Janssen Scientific Affairs, LLC | 1 | $5,860 |
| Sanofi | 4 | $5,742 |
| Boehringer Ingelheim | 2 | $4,825 |
| Argenx US, Inc. | 1 | $2,625 |
| Amgen | 3 | $2,091 |
| UCB, Inc. | 1 | $1,500 |
| Almirall LLC | 1 | $800 |
| Janssen Research & Development, LLC | 1 | $452 |
| Sun Pharmaceutical Industries Inc. | 1 | $147 |
| Novartis | 2 | $48 |
| Arcutis Biotherapeutics, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$368,259 in reported general payments places this provider in the 95th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 97 | $2,098,045 |
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 58 | $968,427 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 43 | $454,001 |
| Dupixent SyringeDupilumab | 75 | $350,184 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 34 | $313,653 |
| RinvoqUpadacitinib | 30 | $185,004 |
| Dupixent PenDupilumab | 45 | $173,616 |
| XeljanzTofacitinib Citrate | 27 | $121,404 |
| Mycophenolic AcidMycophenolate Sodium | 16 | $12,406 |
| Mycophenolate Mofetil | 50 | $7,705 |
| Ketoconazole | 43 | $3,226 |
| Colchicine | 17 | $2,983 |
| Hydroxychloroquine Sulfate | 70 | $2,799 |
| Pentoxifylline | 38 | $2,648 |
| Betamethasone Dipropionate | 31 | $2,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerOctagam, Panzyga, Xeljanz | $25,222 | $3,187,877182 claims |
| AbbVieRinvoq | $27,905 | $185,00430 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 552 dermatology providers in Massachusetts.
Other dermatology in Boston
- Alexandra KimballBoston$680K
- Arash MostaghimiBoston$591K
- Brian HiblerBoston$498K
- Maryanne SennaBoston$430K
- Gabriela CobosBoston$343K
- Martina PorterBoston$220K
- Mathew AvramBoston$209K
- Emmy GraberBoston$159K
- Neelam VashiBoston$156K
- Emily RuizBoston$112K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.